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ABSTRACT 
Objective: This study aimed to compare continuous and pro re nata (PRN) proton pump inhibitor (PPI) treatments for laryngopharyngeal reflux (LPR). 
Methods: This randomized clinical trial included 52 LPR patients with lingual tonsil hypertrophy (LTH). Those patients who showed LPR 
improvement with an initial PPI trial were randomly divided into continuous and PRN PPI treatment groups. The Reflux Symptom Index (RSI) score, 
Reflux Finding Score (RFS), and LTH grade were used to assess the treatment results. 
Results: The PPI treatment (30 mg of lansoprazole twice daily) for 6 mo resulted in a significantly decreasing RSI score (p<0.001). The PPI 
treatments for the first 8 w and the second 8 w also showed significant LPR improvement. However, there was no significant improvement after the 
third 8 w (p>0.05). After 6 mo, the PPI treatment also resulted in a continuous decrease in the RFS (p<0.001). There were no significant differences 
in the mean RSI scores (p=0.518) and mean RFSs (p=0.393) between the continuous and PRN PPI groups. In the grade II LTH cases, there was a 
significant improvement after 6 mo of PPI treatment (p<0.001), although there was no improvement after the first 2 mo in the treatment group. For 
the grade III LTH cases, there was no significant improvement after the first 2 mo and 6 mo of the PPI treatment. 
Conclusion: Six months of PPI treatment improved the RSI score, RFS, and LTH grade, although there was no difference between the continuous 
and PRN PPI treatment groups.  
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INTRODUCTION 
Laryngopharyngeal reflux (LPR) disease is the backflow of 
extraesophageal gastric fluid into the larynx, pharynx, trachea, and 
bronchus, which may lead to various symptoms, such as a dry cough, 
globus sensation, dysphonia, throat clearing, postnasal drip, and 
dysphagia [1-3]. The LPR symptoms are different from typical 
gastroesophageal reflux disease (GERD) symptoms, which include 
esophagitis [1, 2]. Belafsky et al. developed a 9-item Reflux Symptom 
Index (RSI) and an 8-item Reflux Finding Score (RFS) for the 
evaluation of laryngeal abnormalities caused by LPR [4, 5]. 
Empirical therapy using proton-pump inhibitors (PPIs) for both 
diagnostic testing and LPRD and GERD treatment has become widely 
accepted [6]. Not only are PPIs noninvasive and simple to use, but 
they can also provide a rational and reasonable value to the 
treatment of these patients. Until now, there have been no studies 
examining the PPI treatment efficacy in LPRD patients. Therefore, 
this study was designed to ascertain the responses to continuous or 
pro re nata (PRN) PPI treatment based on the LPR improvement 
using the RSI and RFS results and the lingual tonsil hypertrophy 
(LTH) degree. 
MATERIALS AND METHODS 
This study included 83 dysphagia patients presenting to the Dysphagia 
Clinic of the Otorhinolaryngology–Head and Neck Surgery, Faculty of 
Medicine, University of Indonesia–Dr. Cipto Mangunkusumo Hospital 
in Jakarta, Indonesia. The medical histories of these patients were 
obtained, as well as the RSI, RFS, general ear, nose, and throat 
examination, and fiberoptic nasopharyngolaryngoscopy examination 
results in order to determine the LTH and LPR degrees. The ethical 
approval for this study was granted by the Ethics Committee of the 
Faculty of Medicine at the University of Indonesia. 
All of the patients were informed about the procedures involved in 
this research both verbally and in writing, and they all signed 
consent forms. After obtaining written consent, each patient was 
given 30 mg of lansoprazole twice daily to establish an early 
diagnosis and as reflux therapy. Of the 83 patients, 19 were not 
involved in the randomization because they did not return after this 
research stage. For those patients who returned, if there was 
symptom improvement, the PPI regimen continued for 2 mo. After 
this, the patients were randomly divided into two groups: a 
continuous treatment group and a PRN treatment group. Each of the 
patients in the continuous treatment group was maintained on the 
30 mg of lansoprazole twice daily treatment regimen. However, the 
patients in the PRN group were given 30 mg of lansoprazole twice 
daily only when they complained of symptoms, and the duration of 
the treatment was self-determined by each patient. Of the 64 
remaining patients who participated in this study, 7 patients and 5 
patients were lost to follow-up in fourth and sixth months, 
respectively; therefore, 52 patients participated through the end of 
this study. 
The data analysis was conducted using IBM SPSS Statistics for 
Windows version 23.0 (IBM Corp., Armonk, NY, USA). A univariate 
analysis was used for descriptive statistics. A repeated analysis of 
variance hypothesis test for 2 independent groups was used for the 
nominal independent variables (continuous PPI and PRN PPI) and 
the numerical dependent variables. 
RESULTS 
In total, 52 patients completed this study: 25 in the continuous 
group and 27 in the PRN group. Thirty-five of these patients (67.3%) 
were females and 17 (32.7%) were males. The number of patients in 
the 40–69 y old age group (59.6%) was greater than that in the 20–
39 y old age group (40.4%). More than one half of the total patients 
(55.7%) were in the moderate economic level category; 25% were in 
the higher economic level category, and 19.3% were in the lower 
economic level category. There were no significant differences 
between the continuous PPI and PRN PPI patient groups with regard 
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to the sex, age, and economic level. 
After 6 mo of PPI treatment, the patients showed improvements in 
their symptom complaints, clinical signs, RSI scores, RFSs, and LTH 
degrees. However, there were no significant differences between the 
improvements in the mean RSI score (p=0.518) and mean RFS (p= 
0.393) between the continuous PPI group and the PRN PPI group. 
The 6-month RSI results for the continuous PPI and PRN PPI groups 
can be seen in fig. 1.  
After the first 8 w, the PPI treatment results showed statistically 
significant improvements in the patients’ complaints. The mean RSI 
score after the first eight weeks of the PPI treatment improved from 
21.83±6.80 to 7.88±5.19 (p<0.001), and after the second 8 w of 
treatment, the mean score further improved to 4.23±2.65 (p<0.001). 
However, the additional 8 w of PPI treatment did not significantly 
improve the mean RSI score (2.96±2.35, p>0.05). There was a 
significant difference between the mean RSI score before treatment 
and the mean score after 6 mo of PPI treatment (p<0.001), but there 
was no significant difference in the mean RSI score between the 
continuous treatment group and the PRN treatment group (p=0.518) 
(fig. 1). 
 
Legends: RSI: reflux symptom index PPI: proton pump inhibitor 
 
Fig. 1: RSI score of continuous and pro re nata (PRN) PPI treatment groups in the following six months 
 
Both the continuous and PRN PPI treatments improved the clinical signs 
in the laryngeal area. As shown in fig. 2, there was an improvement in the 
mean RFS score (from 10.98±2.52 to 7.97±2.45) after the first 8 w of 
treatment (p<0.001). The mean RFS score improved again after the 
second 8 w of treatment to 6.54±2.01 (p<0.001) and again to 4.73±1.95 
(p<0.001) after the third 8 w of treatment. The mean RFS scores slowly 
and continuously improved along with an improvement in the laryngeal 
area clinical signs through the 6 mo of PPI treatment. However, there 
was no significant difference between the continuous PPI group and the 
PRN PPI group (p=0.393) (fig. 2). 
 
 
Legends: -RFS: reflux finding score,-PPI: proton pump inhibitor 
Fig. 2: RFS score of continuous and pro re nata (PRN) PPI treatment groups in the following six months 
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As shown in Tables 1 and 2, 2 mo of the twice-a-day continuous PPI 
dosing resulted in grade improvements, from LTH grade III to grade 
II and from LTH grade III to grade I in 44.1% and 8.8% of the 
patients, respectively. Although there were no grade improvements 
after 2 mo of the PPI treatment, there were grade improvements to 
LTH grade I in 16.7% of patients in the continuous PPI group and 
11.1% of the patients in the PRN PPI group after continuing the 
treatment for 4 mo. However, there were no further improvements 
after 6 mo of PPI treatment in either the continuous PPI group or the 
PRN PPI group. 
 
Table 1: Lingual tonsil hypertrophy grading at the initial assessment, the second week of treatment, fourth week of treatment, and eighth 
week of treatment 
 Initial grade of lingual tonsil hypertrophy Post PPI therapy of lingual tonsil hypertrophy 
1 (n/%) 2 (n/%) 3 (n/%) Total (n/%) 
Second week 1 10 (100) 0 (0) 0 (0) 10 (100) 
 2 0 (0) 33 (100) 0 (0) 33 (100) 
 3 0 (0) 0 (0) 40 (100) 40 (100) 
 Total 10 (12.0) 33 (39.8) 40 (48.2) 83 (100) 
Fourth week 1  7 (100) 0 (0) 0 (0) 7 (100) 
 2  5 (20.0) 20 (80) 0 (0) 25 (100) 
 3  0 (0) 10 (29.4) 24 (70.6) 34 (100) 
 Total 12 (18.2) 30 (45.5) 24 (36.4) 66 (100) 
Eight week 1 7 (100) 0 (0) 0 (0) 7 (100) 
 2 12 (52.2) 11 (47.8) 0 (0) 23 (100) 
 3 3 (8.8) 15 (44.1) 16 (47.1) 34 (100) 
 Total 22 (34.4) 26 (40.6) 16 (25) 64 (100) 
 
Table 2: Lingual tonsil hypertrophy grading after the fourth month of treatment and the sixth month of treatment 
 After-eight-week treatment grade Post PPI treatment grade of lingual tonsil hypertrophy 
   1 (n/%) 2 (n/%) 3 (n/%) Total (n/%) p 
Fourth month 1 continuous 11 (100) 0 (0) 0 (0) 11 (100)  
  pro re nata 8 (100) 0 (0) 0 (0) 8 (100)  
 Total  19 (100) 0 (0) 0 (0) 19 (100)  
        
 2 continuous 6 (54.5) 5 (45.5) 0 (0) 11 (100) 0.024 
  pro re nata  1 (8.3) 11 (91.7) 0 (0) 12 (100)  
 Total  7 (30.4) 16 (69.6) 0 (0) 23 (100)  
        
 3 continuous 1 (16.7) 2 (33.3) 3 (50.0) 6 (100) 0.969 
  pro re nata 1 (11.1) 7 (77.8) 1 (11.1) 9 (100)  
 Total  2 (13.3) 9 (60.0) 4 (26.7) 15 (100)  
        
Sixth month 1 continuous 8 (100) 0 (0) 0 (0) 8 (100)  
  pro re nata 7 (100) 0 (0) 0 (0) 7 (100)  
 Total  15 (100) 0 (0) 0 (0) 15 (100)  
        
 2 continuous 8 (72.7) 3 (27.3) 0 (0) 11 (100) 0.01 
  pro re nata 2 (18.2) 9 (81.8) 0 (0) 11 (100)  
 Total  10 (45.5) 12 (54.5) 0 (0) 22 (100)  
        
 3 continuous 1 (16.7) 5 (83.3) 0 (0) 6 (100) 0.696 
  pro re nata 1 (11.1) 7 (77.8) 1 (11.1) 9 (100)  
 Total  2 (13.3) 12 (80.0) 1 (6.7) 15 (100)  
 
In the LTH grade II patients, there were improvements to LTH grade 
I in 52.2% of the patients after 2 mo of the PPI treatment. However, 
even though the condition remained the same (LTH grade II) after 2 
mo of the PPI treatment, the continuous PPI treatment provided 
better results (72.7%) than the PRN PPI treatment (18.2%). 
There was a significantly different LTH degree improvement 
between the two groups after 6 mo of treatment (p<0.001). 
Moreover, the continuous PPI group showed better overall 
improvement when compared to the PRN PPI group, although the 
difference was not significant (p=0.158).  
DISCUSSION 
In LPR cases, the reliability of 24 h pH monitoring has been 
questioned because it has poor sensitivity, poor specificity, and poor 
positive and negative predictive values [7]. Therefore, efforts have 
been made to improve the clinical examination reliability in order to 
identify LPR patients. Many researchers have used the RSI created 
by Belafsky et al., which is a 9-item, self-administered, disease-
specific outcome instrument based on LPR symptoms. The item 
scores range from 0 (no complaints) to 5 (heavy sigh), with a 
maximum score of 45, and RSI values>13 are considered to be 
abnormal [4]. Belafsky et al. also created the RFS, which is an 8-item 
clinical severity scale based on a patient’s videolaryngoscopic 
findings. The scores range from 0 (no abnormal findings) to a 
maximum of 26 (worst possible score) [5, 8]. Generally, an LPR 
diagnosis is made using a combination of the patient’s history, 
symptoms, and endoscopic assessment results. Additionally, 
Campagnolo et al. suggested the use of a therapeutic PPI trial as a 
cost-effective and useful diagnostic test [2, 9]. The results of our 
study showed significant RSI score improvements with 6 mo of PPI 
treatment (from 21.83±6.80 to 2.96±2.35). This indicates that 6 mo 
of PPI treatment improved the patients’ symptoms as assessed by 
the RSI score. Habermann et al. [10] also found RSI score 
improvements in their study after 12 w of treatment with 40 mg of 
pantoprazole daily. The median total RSI score before treatment was 
12 (range=10–41), which decreased significantly to 3 (range=0–44) 
at the end of the treatment (p<0.001) [10]. In our study, there were 
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significant improvements after 2 and 4 mo of the PPI treatment in 
both groups. However, the complaints remained the same, despite 
further therapy, up to the sixth month. These complaints could be 
further improved with dietary and lifestyle modifications, such as 
smoking cessation, weight loss, avoiding caffeine, and head-of-the-
bed elevation [11]. Pearson et al. [12]. Reported that dietary and 
behavior changes were very effective for the management of LPR in 
a UK district general hospital. 
Sataloff et al. [13] had findings consistent with the first observation 
by Aviv in 1993 using the Flexible Endoscopic Evaluation of 
Swallowing with Sensory Testing, in which they found diminished 
sensory thresholds in the LPR patients. We used the RFS to assess 
the laryngeal area abnormalities, and our results showed that the 
mean RFS before treatment was 10.98±2.5. There were significant 
improvements after 2 mo (7.96±2.4), 4 mo (6.54±2.1), and 6 mo 
(4.73±1.9) of PPI treatment (p<0.05). Our results also showed that 
there was no significant difference in the mean RFSs between the 
continuous PPI group and the PRN PPI group. However, the results
CONCLUSION 
 
did show that the PPI treatment improved the RFS with both the 
continuous and PRN PPI treatments. The results of the study by 
Patigaroo et al.[14] showed that the mean RFS before the PPI 
treatment in 50 patients was 12, and that the most common 
laryngeal findings were laryngeal hyperemia, ventricular 
obliteration, and posterior commissure hypertrophy. The mean RFSs 
after 8 w and 16 w of the PPI treatment decreased significantly to 
9.5 and 6.5, respectively [14]. 
The RFS was designed to be an objective scoring system used to 
assess laryngeal area abnormalities. It has also been used to monitor 
the LPR progression and response to treatment. However, it is still 
unclear whether the results of both the RSI and RSF can be used to 
guide the treatment of suspected LPR [3, 10]. 
No previous studies have reported the effects of PPI treatment on 
LTH. In our study, there were LTH grade improvements that 
narrowed significantly after 6 mo of PPI treatment (p<0.001), 
although the difference between the continuous and PRN PPI groups 
was not significant (p=0.158).  
If we were to compare the outcomes from each baseline grade, not 
all of LTH grades would improve with PPI treatment. If there is no 
improvement in an LTH grade III patient after 2 mo of PPI treatment, 
continuing the PPI treatment up to 6 mo might only provide a little 
improvement. Therefore, other treatment options should be 
considered. Contrarily, when there is improvement in an LTH grade 
II patient after 2 mo of PPI treatment, this patient should continue 
the PPI treatment continuously for up to 6 mo. 
PPIs inhibit the maximal acid output when they are taken before a 
meal in the morning and in the evening [15]. However, there is no 
research suggesting a PRN PPI treatment for LPR patients. If a PPI 
treatment is continuous, the patient will spend more money for 6 mo 
of treatment. 
The PPI treatment consisting of 30 mg of lansoprazole twice daily 
for 6 mo improved the RSI scores during the first 2 mo and the 
second 2 mo. However, further PPI treatment for the third 2 mo did 
not provide any improvement. Overall, there was a significant 
difference between mean RSI scores before and after the PPI 
treatment. Additionally, both the continuous and PRN PPI 
treatments improved the clinical signs in the larynx and the 
surrounding area, as shown by the slow and continuous RFS 
decrease for up to 6 mo of PPI treatment. 
The PPI treatment resulted in a decreasing degree of LTH. In those 
patients that are PPI resistant during the first 2 mo, the PPI 
treatment should continue through 4 mo for LTH grade II cases. For 
LTH grade III cases, other treatment options should be considered. 
LIMITATIONS 
The unavoidable limitation of this study was that not all of the 
eligible patients were willing to participate. Additionally, some of the 
patients were lost to follow-up during the intervention period. 
Including a larger number of patients in a similar study could help to 
make the results more generalizable and representative of this 
patient population. 
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